Abpro Holdings, Inc.

ABPO

US0008472021

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 2026-04-17			5-day change	1st Jan Change
0.1442 ^USD	-3.87%		+38.65%	-96.59%

Apr. 15	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 24	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI

Abpro Holdings files prospectus related to the offer and resale of up to 9.78 million shares of common stock - SEC filing

Published on 11/07/2025 at 07:49 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Abpro Holdings, Inc.

Apr. 15	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 24	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI
Feb. 19	Abpro Holdings, Inc.(OTCPK:ABPO) dropped from NASDAQ Composite Index	CI
Feb. 03	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
Jan. 23	Abpro Holdings, Inc. Announces Board and Committee Changes	CI
Jan. 16	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding	CI
Jan. 06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
Jan. 06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
Dec. 15	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers	RE
Dec. 15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
Nov. 14	Abpro Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 07	Abpro Holdings files prospectus related to the offer and resale of up to 9.78 million shares of common stock - SEC filing	RE
25-10-22	Abpro Holdings Inc - to effect one-for-thirty reverse stock split - SEC filing	RE
25-10-02	Abpro Holdings, Inc. Announces Termination of Robert J. Markelewicz as Chief Medical Officer, Effective November 30, 2025	CI
25-08-13	Abpro Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The Company is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patientâ€™s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.

Employees

Sector

Biotechnology & Medical Research

More about the company